Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report
Authors He W, Zhang XM, Li WW, Kong C, Wang YY, Zhu LY, Xu RL, Deng GF, Zhang PZ
Received 26 June 2018
Accepted for publication 6 September 2018
Published 24 October 2018 Volume 2018:11 Pages 7423—7427
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Arseniy Yuzhalin
Wan He,1,* Xiangmei Zhang,2,* Wenwen Li,1 Cheng Kong,1 Yuanyang Wang,3 Lianyu Zhu,1 Ruilian Xu,1 Guofang Deng,4 Peize Zhang4
1Department of Oncology, The Second Clinical Medical College, Shenzhen People’s Hospital, Jinan University, Shenzhen, Guangdong 518020, China; 2Department of Pathology, The Third People’s Hospital of Shenzhen, Shenzhen, Guangdong 518112, China; 3Department of Surgery, The Second Clinical Medical College, Shenzhen People’s Hospital, Jinan University, Shenzhen, Guangdong 518020, China; 4Department of Pulmonary Medicine, The Third People’s Hospital of Shenzhen, Shenzhen, Guangdong 518112, China
*These authors contributed equally to this work
Background: PD-1 checkpoint inhibitors have shown a robust tumor response in the treatment of various cancers. Pembrolizumab is an anti-PD-1 checkpoint antibody approved for the treatment of unresectable or metastatic melanoma in more than 40 countries. Although autoimmune pneumonitis is considered a common immune-related adverse event of PD-1 inhibitors, only limited studies have assessed the development of opportunistic infections such as pulmonary tuberculosis (TB).
Case presentation: A patient with metastatic melanoma whose pulmonary TB was activated after administration of pembrolizumab for melanoma is reported. Anti-TB drugs were administered, followed by pembrolizumab (2 mg/kg, repeated every 28 days), which successfully cured the TB and achieved complete response for melanoma.
Conclusion: Activated pulmonary TB was observed during the administration of pembrolizumab. It was safe and effective in the current patient to combine anti-TB drugs and PD-1 inhibitors. More importantly, screening pulmonary TB before administration of PD-1 inhibitors is recommended.
Keywords: checkpoint inhibitor, PD-1, pembrolizumab, metastatic melanoma, pulmonary tuberculosis, anti-tuberculosis treatment
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]